SLN.L Regulatory News (SLN)

11 Jul 2005 12:12

SR Pharma plc ("SR Pharma" or "the Company")Result of EGM11 July 2005At the extraordinary general meeting ("EGM") of the Company held earlier today,the single resolution put to shareholders was passed, approving the acquisitionof Atugen AG that was first announced on 21 June 2005.The 22,820,736 SR Pharma shares being issued as consideration to the Atugenshareholders will be admitted to trading on AIM tomorrow, 12 July 2005, atwhich point, the acquisition of approximately 96% of the issued share capitalof Atugen by the Company will complete. It is intended that the minorityshareholdings in Atugen will be acquired by the Company in due course.Following admission of the enlarged share capital to trading on AIM("Admission"), there will be 46,706,450 Ordinary Shares of 1p each in SR Pharmain issue.Following today's EGM, Jeremy Curnock Cook. Dr David U'Prichard and ProfessorBernd Wetzel have been appointed as Non-executive Directors of SR Pharma witheffect from Admission.Further information:Melvyn DaviesCompany SecretarySR Pharma plcTel: 020 7307 1620 Page 1ENDSR PHARMA PLC